Search

Displaying results 4721 - 4730 of 9333 in total
  1. Drug

    Morniflumate

    go.drugbank.com/drugs/DB09285
    Investigational

    It is the morpholinoethyl ester of niflumic acid [L1496]. In one study, post morniflumate ingestion, physical examination and clinical symptoms of those with bronchitis showed improvement [A7889].

  2. Drug

    RTA 744

    go.drugbank.com/drugs/DB05920
    Investigational

    Anthracyclines are one of the most broadly used and effective classes of cancer therapies; however, they are not used to treat brain cancers because current therapies do not cross the blood-brain barrier … RTA 744 is a novel anthracycline derivative that crosses the blood-brain barrier and shows significant potential for the treatment of primary and metastatic brain cancers.

  3. Drug

    N-hydroxy-4-({4-[4-(trifluoromethyl)phenoxy]phenyl}sulfonyl)tetrahydro-2H-pyran-4-carboxamide

    go.drugbank.com/drugs/DB06945
    Experimental

    This compound belongs to the diarylethers. These are organic compounds containing the dialkyl ether functional group, with the formula ROR', where R and R' are aryl groups. … This substance is known to target a disintegrin and metalloproteinase with thrombospondin motifs 5.

  4. Drug

    Lomedeucitinib

    go.drugbank.com/drugs/DB21649
    Investigational

    The usage of the INN stem '-citinib' in the name indicates that Lomedeucitinib is a Janus kinase inhibitor. … Lomedeucitinib is under investigation in clinical trial NCT05730725 (A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis).

  5. Drug

    Satavaptan

    go.drugbank.com/drugs/DB14923
    Investigational

    Satavaptan is under investigation in clinical trial NCT00359437 (Satavaptan in the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver).

  6. Drug

    7,8-dihydrobiopterin

    go.drugbank.com/drugs/DB04400
    Experimental

    7,8-Dihydrobiopterin is an inhibitor of the enzyme dihydroneopterin aldolase (DHNA), which catalyzes the conversion of 7,8-Dihydrobiopterin to 6-hydroxymethyl-7,8-dihydropterin and glycolaldehyde.

  7. Drug

    Pradefovir mesylate

    go.drugbank.com/drugs/DB05478
    Investigational

    As adefovir is poorly absorbed and associated with a high level of nephrotoxicity, pradefovir mesilate was designed to specifically target the liver and reduce risks to external tissue, especially the … Pradefovir is undergoing phase II development for the treatment of chronic hepatitis B.

  8. Drug

    Elacytarabine

    go.drugbank.com/drugs/DB05494
    Investigational

    Elacytarabine is a patented new chemical entity of the nucleoside analog class, with improved biological properties and the potential to treat solid tumours such as non-small cell lung cancer, malignant … Cytarabine has limitations such as minimal uptake in solid tumours and is only used to treat leukaemia.

  9. Drug

    Vapitadine

    go.drugbank.com/drugs/DB05738
    Experimental

    An advantage of vapitadine over other antihistamines may be the absence of the sedation, even at high doses. … Vapitadine is an antihistamine that Barrier Therapeutics is developing as a treatment for allergic reactions of the skin, such as those associated with hives and for the itch associated with atopic dermatitis

  10. Drug

    Rebamipide

    go.drugbank.com/drugs/DB11656
    ApprovedInvestigational

    Rebamipide has been investigated for the treatment of Stomach Ulcer, Keratoconjunctivitis Sicca, and Gastric Adenoma and Early Gastric Cancer.